GENE ONLINE|News &
Opinion
Blog

First Potential Treatment for COVID-19 Greenlighted by Korean Authorities

by GeneOnline
Share To

South Koreas’ Ministry of Food and Drug Safety has approved the application from Seoul National University Hospital (SNUH) and ImmuneMed to use its patented virus suppressing factor (VSF) as a COVID-19 treatment.

The COVID-19 viral epidemic has been rapidly spreading to newer areas around the world and South Korea is one of the many countries that currently battles with the disease. At the time of writing, estimates suggest 7,041 confirmed cases with 46 fatalities in the country. The massive contagion in Daegu, South Korea has struck alarm in the lives of many Korean citizens including authorities. Several steps have been taken to prevent further spread, and the government is looking for more detection kits and available medication. Late last month, South Korean biotech, PCL, Inc. released a breakthrough testing kit, called COVID-19 Ag GICA Rapid, to detect infection in 10 minutes with 85% accuracy. Around the same time, the application of using VSF as COVID-19 treatment was approved to support contingency measures.

VSF is an interferon-like molecule first observed in mouse models, which was later also found in humans. As an endogenously secreted agent, it can defend the attacks from viruses by binding to the surface protein on infected cells and adjusting inflammatory proteins to inhibit the virus reproduction and further inflammation. Chuncheon-based ImmuneMed used the mouse VFS prototype and modified it into a more effective and compatible one for humans. The modified HzVSFs shows better anti-viral ability and safety at the preclinical and phase I trials. Results show that 70% of the mice infected with a fatal titer of coronavirus were protected by the treatment. Besides COVID-19, ImmuneMed has also prepared to apply VSF to deadly influenza and Hepatitis B. The world is looking forward to the success of new agents such as these to minimize the deadly effects of this vicious virus.

Related article: Antiviral Drug Developed By Emory University Shows Effectiveness against Coronaviruses

References

  1. http://www.immunemed.co.kr/kor/news/news.asp?mode=read&sno=4313

 

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
Ascletis Cleared By FDA To Begin Trial On Monkeypox Antiviral
2022-11-16
CDC Warns Of “Tripledemic” Winter Amid Rising Flu And RSV Cases
2022-11-14
Sanofi, GSK Secure European COVID-19 Booster Approval, AstraZeneca Withdraws U.S. Application
2022-11-10
LATEST
Targeting Metabolism for Noninvasive Multi-Cancer Early Detection Tests
2022-12-08
Moderna’s Personalized Cancer Therapy: The New Transformative Approach to Oncology
2022-12-08
SK Biopharmaceuticals' Partner Angelini Pharma Launches Cenobamate in France
2022-12-08
Relmada Blames ‘Implausible Placebo Results’ on Depression Drug’s Failure Again
2022-12-07
Using Sound Waves to Sort Blood-Based Nanoparticles
2022-12-07
Summit Bets $5 Billion On Akeso’s Bispecific Antibody
2022-12-07
Pharming announces publication of data from Phase 3 Study of leniolisib in patients with APDS in ASH's Blood
2022-12-07
EVENT
2022-12-10
64TH ASH ANNUAL MEETING & EXPOSITION
New Orleans, USA
2022-12-14
BIOHK2022
Hong Kong, China
2022-12-21
Avatar Medicine Forum
Online
2023-01-07
7th Asia Microbiome Conference
Taipei, Taiwan
2023-01-09
JPM Annual Healthcare Meeting 2023
San Francisco, USA
Scroll to Top

Create an account with us now to say goodbye to all the pop-ups!